DNA Biomed Solns - Asset Resilience Ratio

Latest as of June 2021: 3.82%

DNA Biomed Solns (DNA) has an Asset Resilience Ratio of 3.82% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DNA total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

ILA2.35 Million

≈ $6.29K USD Cash + Short-term Investments

Total Assets

ILA61.52 Million

≈ $164.92K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2019)

This chart shows how DNA Biomed Solns's Asset Resilience Ratio has changed over time. See DNA Biomed Solns book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down DNA Biomed Solns's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DNA Biomed Solns (DNA) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA2.35 Million	3.82%
Total Liquid Assets	ILA2.35 Million	3.82%

Asset Resilience Insights

Limited Liquidity: DNA Biomed Solns maintains only 3.82% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

DNA Biomed Solns Industry Peers by Asset Resilience Ratio

Compare DNA Biomed Solns's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for DNA Biomed Solns (2011–2019)

The table below shows the annual Asset Resilience Ratio data for DNA Biomed Solns.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2019-12-31	7.62%	ILA2.80 Million ≈ $7.51K	ILA36.73 Million ≈ $98.49K	-3.20pp
2016-12-31	10.82%	ILA4.13 Million ≈ $11.08K	ILA38.17 Million ≈ $102.34K	-5.29pp
2013-12-31	16.12%	ILA3.33 Million ≈ $8.94K	ILA20.68 Million ≈ $55.45K	+2.62pp
2012-12-31	13.50%	ILA2.86 Million ≈ $7.67K	ILA21.20 Million ≈ $56.84K	+7.30pp
2011-12-31	6.20%	ILA1.04 Million ≈ $2.80K	ILA16.82 Million ≈ $45.10K	--

pp = percentage points

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$34.04 Million

ILA12.70 Billion ILA

Market Cap Rank

#23386 Global

#332 in Israel

Share Price

ILA103.10

Change (1 day)

-3.64%

52-Week Range

ILA86.50 - ILA147.50

All Time High

ILA1900.80